Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.30    0.075 (6.12%)
Bid:
1.20
Ask:
1.40
Spread: 0.20 (16.667%)
Market Cap: £20.87m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Holding(s) in Company

1 Dec 2009 17:34

RNS Number : 4264D
Epistem Holdings plc
01 December 2009
Β 

ο»Ώ

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1.Β Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Epistem Holdings plc

2. Reason for the notification Β (please tick the appropriate box or boxes)

An acquisition or disposal of voting rightsΒ 

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An event changing the breakdown of voting rights

Other (please specify):Change in percentage ownership following a change in issued share capital subsequent to the placing announced on 20 November 2009

x

3. Full name of person(s) subject to the notification obligation:

Octopus InvestmentsΒ NomineesΒ Limited

4. Full name of shareholder(s)Β (if different from 3.):

5. Date of the transactionΒ (and date on which the threshold is crossed or reached if different):

27 November 2009

6. Date on which issuer notified:

1 DecemberΒ 2009

7. Threshold(s) that is/are crossed or reached:

5%

8. Notified details:

n/a

A: Voting rights attached to shares

Class/type of sharesΒ 

Β if possible using the ISIN CODE

Situation previous to the Triggering transactionΒ 

Resulting situation after the triggering transaction

Number of SharesΒ 

Number of Voting RightsΒ 

Number of sharesΒ 

Number of voting rightsΒ 

% of voting rights

Direct

Direct

IndirectΒ 

Direct

Indirect

GB00B1VKB244

364,300

364,300

364,300

364,300

Β -

4.59%

-

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrumentΒ 

Expiration dateΒ 

Exercise/ Conversion Period/ DateΒ 

Number of voting rights that may be acquired if the instrument is exercised/ converted.Β 

% of voting rights

-

-

-

-

-

Total (A+B)

Number of voting rights

% of voting rights

364,300

4.59%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

n/a

Proxy Voting:

10. Name of the proxy holder:

n/a

11. Number of voting rights proxy holder will cease to hold:

n/a

12. Date on which proxy holder will cease to hold voting rights:

n/a

13. Additional information:

-

14. Contact name:

Russell Jarvis

15. Contact telephone number:

020 7710Β 8653

16. Contact at Epistem Holdings Plc

Matthew Walls

+44 (0) 7887 501 998

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
HOLUAOBRKRRURAA
Date   Source Headline
18th Jun 20267:00 amRNSManchester NHS Trust transitions MT-RNR1 to BAU
5th Jun 20267:00 amRNSReceipt of R&D tax credit
1st Jun 20267:00 amRNSBlock Listing Returns
26th May 20267:00 amRNSBoard Changes
6th May 202611:56 amRNSHolding(s) in Company
5th May 20267:00 amRNSSussex NHS Trust transitions MT-RNR1 test to BAU
21st Apr 20267:00 amRNSNHS England commercial strategy for MT-RNR1
20th Apr 20267:00 amRNS-RInteractive Investor Hub Updates
16th Apr 20267:00 amRNSCYP2C19 kit implemented in North Bristol NHS Trust
30th Mar 20267:00 amRNSInterim Results to 31 December 2025
12th Mar 20269:52 amRNSHolding(s) in Company
12th Mar 20267:00 amRNSHolding(s) in Company
12th Mar 20267:00 amRNSHolding(s) in Company
11th Mar 20263:22 pmRNSHolding(s) in Company
11th Mar 20263:22 pmRNSHolding(s) in Company
9th Mar 202611:29 amRNSResult of General Meeting
9th Mar 20267:00 amRNSResult of Open Offer and Additional Subscriptions
24th Feb 20262:32 pmRNSHolding(s) in Company
24th Feb 202612:05 pmRNSHolding(s) in Company
19th Feb 20267:00 amRNSPublication of circular, notice of GM & timetable
13th Feb 20264:22 pmRNSCompletion of Placing
13th Feb 20262:04 pmRNSProposed Direct Subscription to raise up to £3.5m
6th Feb 20269:50 amRNSHolding(s) in Company
3rd Feb 202610:59 amRNSHolding(s) in Company
27th Jan 20262:18 pmRNSHolding(s) in Company
19th Jan 20263:01 pmRNSProposed equity raise of up to £6.0 million
31st Dec 202511:44 amRNSResult of AGM
31st Dec 202511:44 amRNSResult of AGM
18th Dec 20257:00 amRNSScotland NHS “test of change” pilot programme
11th Dec 20259:00 amRNSNew interactive investor hub
9th Dec 20253:45 pmRNSAgreement of Shareholder Loan
8th Dec 20254:00 pmRNSAnnual Report and Accounts and date of AGM
5th Dec 20257:00 amRNSFinal Results
3rd Dec 20257:00 amRNSNotice of Results
1st Dec 20253:19 pmRNSBlock Listing Returns
1st Dec 20257:00 amRNSResults presented re. NHS CYP2C19 Genotype Testing
27th Nov 202510:09 amRNSNHS implementation guide published for CYP2C19
26th Nov 20257:00 amRNSScotland national roll-out of MT-RNR1 ID Kit
19th Nov 20257:00 amRNSFurther re Shareholder Loan
4th Nov 20257:00 amRNSMT-RNR1 ID Kit in Dublin’s Rotunda Hospital
31st Oct 20257:00 amRNSPotential Shareholder Loan
29th Oct 20254:35 pmRNSHolding(s) in Company
28th Oct 20257:00 amRNSMOU with Kingdom of Saudi Arabia for MT-RNR1 ID
24th Oct 20254:30 pmRNSApplication for Listing & Total Voting Rights
15th Oct 202510:49 amRNSResult of General Meeting
10th Oct 20251:32 pmRNSHolding(s) in Company
10th Oct 20251:31 pmRNSHolding(s) in Company
10th Oct 20259:00 amRNSHolding(s) in Company
9th Oct 202510:23 amRNSFurther re Equity Financing
6th Oct 20257:00 amRNSFurther re Equity Financing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.